Page last updated: 2024-08-24

topotecan and Response Evaluation Criteria in Solid Tumors

topotecan has been researched along with Response Evaluation Criteria in Solid Tumors in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	4 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, GP; Chen, YQ; Hu, JL; Liu, NF; Sun, HY; Yang, Y; Yu, H; Zhu, JQ; Zhu, T	1
Beaumont, H; Chadjaa, M; Evans, TL; Guermazi, A; Hong, SR; Klifa, C; Monostori, Z	1
Bevis, KS; Blansit, K; Chan, JK; ElNaggar, A; Fuh, KC; Huh, W; Kapp, DS; Previs, R; Secord, AA; Tillmanns, T	1
Chadjaa, M; Cho, BC; Evans, TL; Fischer, JR; Martinez, P; Ramlau, R; Shen, L; Shepherd, FA; Syrigos, KN; Udud, K; Wolf, M	1

Trials

2 trial(s) available for topotecan and Response Evaluation Criteria in Solid Tumors

Article	Year
Discrepancies of assessments in a RECIST 1.1 phase II clinical trial - association between adjudication rate and variability in images and tumors selection. Cancer imaging : the official publication of the International Cancer Imaging Society, 2018, Dec-11, Volume: 18, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Observer Variation; Reproducibility of Results; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Risk Factors; Small Cell Lung Carcinoma; Taxoids; Topotecan; Tumor Burden	2018
Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Response Evaluation Criteria in Solid Tumors; Retreatment; Small Cell Lung Carcinoma; Survival Rate; Taxoids; Topotecan	2015

Article

Year

Discrepancies of assessments in a RECIST 1.1 phase II clinical trial - association between adjudication rate and variability in images and tumors selection.

Cancer imaging : the official publication of the International Cancer Imaging Society, 2018, Dec-11, Volume: 18, Issue:1

Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Observer Variation; Reproducibility of Results; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Risk Factors; Small Cell Lung Carcinoma; Taxoids; Topotecan; Tumor Burden

2018

Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:8

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Response Evaluation Criteria in Solid Tumors; Retreatment; Small Cell Lung Carcinoma; Survival Rate; Taxoids; Topotecan

2015

Other Studies

2 other study(ies) available for topotecan and Response Evaluation Criteria in Solid Tumors

Article	Year
Role and timing of second-line therapies for patients with recurrent platinum-resistant ovarian epithelial cancer. European journal of gynaecological oncology, 2017, Volume: 38, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Response Evaluation Criteria in Solid Tumors; Retreatment; Retrospective Studies; Survival Rate; Topotecan	2017
Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients. Gynecologic oncology, 2015, Volume: 139, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Doxorubicin; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Polyethylene Glycols; Radiography; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate; Taxoids; Topotecan; Young Adult	2015

Article

Year

Role and timing of second-line therapies for patients with recurrent platinum-resistant ovarian epithelial cancer.

European journal of gynaecological oncology, 2017, Volume: 38, Issue:2

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Response Evaluation Criteria in Solid Tumors; Retreatment; Retrospective Studies; Survival Rate; Topotecan

2017

Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.

Gynecologic oncology, 2015, Volume: 139, Issue:3

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Doxorubicin; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Polyethylene Glycols; Radiography; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate; Taxoids; Topotecan; Young Adult

2015